Affiliation:
1. Universidade do Estado do Rio de Janeiro, Brazil
2. UERJ, Brazil
Abstract
Human growth hormone (hGH) replacement therapy has been widely available for clinical purposes for more than fifty years. Starting in 1958, hGH was obtained from cadaveric pituitaries, but in 1985 the association between hGH therapy and Creutzfeldt-Jakob disease was reported. In the same year, the use of recombinant hGH (rhGH) was approved. Side effects of rhGH replacement therapy in children and adolescents include rash and pain at injection site, transient fever, prepubertal gynecomastia, arthralgia, edema, benign intracranial hypertension, insulin resistance, progression of scoliosis, and slipped capital femoral epiphysis. Since GH stimulates cell multiplication, development of neoplasms is a concern. We will review the side effects reported in all rhGH indications.
Subject
General Medicine,Endocrinology, Diabetes and Metabolism
Reference58 articles.
1. Creutzfeldt-Jakob disease in pituitary growth hormone recipients;Fradkin JE;Endocrinologist,1993
2. Current indications for growth hormone therapy in children and adolescents;Richmond E;Endocr Dev,2010
3. Growth hormone deficiency (GHD) from birth to 2 years of age: diagnostic specifics of GHD during the early phase of life;Ogilvy-Stuart AL;Horm Res,2003
4. Management of type 2 diabetes mellitus associated with pituitary gigantism;Ali O;Pituitary,2007
5. Efectividad de la hormona de crecimiento recombinante en el déficit de talla debido a retraso de crecimiento intrauterino;Vicens-Calvet E;Med Clin (Barc).,1999
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献